Heron Therapeutics Inc Stock Price, News & Analysis

Heron Therapeutics (HRTX) presented interim data from a Phase 2 study of ZYNRELEF at the SOAP 54th Annual Meeting. ZYNRELEF, approved for postoperative analgesia, showed low levels of bupivacaine and meloxicam in breast milk post-administration in women undergoing C-sections. Results indicated ZYNRELEF was well-tolerated and effectively reduced postoperative opioid use, with 27% of patients experiencing opioid-free recovery. The findings suggest ZYNRELEF could significantly enhance pain management for postpartum women while minimizing opioid exposure.

Heron Therapeutics (HRTX) reported Q1 2022 net product sales of $23.5 million, marking a year-over-year increase from $20 million. ZYNRELEF unit demand rose by 68%, supported by CMS's approval of a 3-year transitional pass-through status starting April 1, enabling separate reimbursements outside surgical bundle payments. Additionally, the company's oncology care franchise generated $22.4 million in net revenue, a 13% rise over the prior quarter, with full-year guidance set between $89 million and $93 million. However, net loss increased to $63.9 million, or $0.63 per share.

Heron Therapeutics (HRTX) announced a conference call for May 9, 2022, at 4:30 p.m. ET to discuss its first quarter financial results and recent business highlights. The call can be accessed via telephone or web, and an archive will be available for 60 days. The company is focused on developing best-in-class treatments aimed at fulfilling unmet patient needs in acute care and oncology. Caution is advised regarding forward-looking statements due to inherent risks and uncertainties.

Heron Therapeutics, Inc. (Nasdaq: HRTX) will participate in a fireside chat at the 21^st Annual Virtual Needham Healthcare Conference on April 11, 2022, at 8:00 am PT. The event aims to discuss the company's innovative approaches to addressing unmet patient needs in acute care and oncology through best-in-class treatments. A live webcast will be available on the company's website in the Investor Resources section. For more information about Heron and its products, please visit www.herontx.com.

Heron Therapeutics announced that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through status for ZYNRELEF, effective April 1, 2022. This status allows ZYNRELEF to be reimbursed separately in Hospital Outpatient Departments (HOPD) and Ambulatory Surgical Centers (ASC) for three years, enhancing access for patients needing postoperative pain relief. With 72% of ZYNRELEF procedures occurring in outpatient settings, this approval positions Heron advantageously against competitors. ZYNRELEF is the first dual-acting local anesthetic approved for up to 72 hours of pain relief following various surgical procedures.

Heron Therapeutics, Inc. announced that Health Canada has approved ZYNRELEF, an extended-release local anesthetic, for postoperative analgesia following specific surgeries. This product is notable as it's the only extended-release bupivacaine approved in Canada, combining bupivacaine and meloxicam to enhance pain relief while reducing opioid use. The company intends to expand ZYNRELEF's indications and reduce costs through manufacturing supplements. This approval is seen as a significant step in addressing the opioid crisis.

Heron Therapeutics, Inc. (Nasdaq: HRTX) will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference on March 7, 2022, at 11:10 am PT. The live webcast will be accessible on their website in the Investor Resources section. As a commercial-stage biotechnology company, Heron focuses on developing innovative treatments for unmet patient needs in acute care and oncology. Their advanced science and patented technologies have led to a unique portfolio aimed at enhancing standards of care. More information is available at www.herontx.com.

Heron Therapeutics, Inc. (HRTX) announced its financial results for Q4 and FY 2021, reporting net product sales of $20.7 million and $86.3 million, respectively. The net loss decreased to $54.6 million for Q4 2021, improving from $62.3 million in Q4 2020. Key highlights include the successful launch of ZYNRELEF, now covering 7 million procedures annually, with net sales reaching $2.9 million. Anticipated guidance for Q1 2022 oncology care franchise sales is $20 million to $22 million. The company aims to moderate cash usage as sales grow.

Heron Therapeutics (HRTX) announced a conference call on February 28, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results along with recent business developments. The call can be accessed via phone or webcast on Heron's website. The company aims to enhance patient care through innovative treatments and is committed to addressing unmet medical needs in acute care and oncology. Further details will be available during the call and afterwards on Heron's website.